Information  X 
Enter a valid email address

Shire plc (SHP)

  Print      Mail a friend       Annual reports

Thursday 08 January, 2015

Shire plc

Director/PDMR Shareholding


Director/PDMR Share Dealings

January 8, 2015 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces
it has been notified that Dr. Steven Gillis, Non-Executive Director of the
Company, was recently informed that American Depositary Shares ("ADSs"), as set
out below, were acquired on his account by an independent third party
exercising discretion over dealing decisions. The transactions took place on
the NASDAQ.

      Date of         Number of ADSs    Average price per ADS  
    transaction           acquired                              
                                                    
                                                               
  October 30, 2014          127                $196.744        
                                                               
 December 19, 2014          76                 $218.16         

Following the above transactions, Dr. Gillis holds 674 ADSs. One ADS is equal
to three ordinary shares of 5 pence each in the Company.

This notification is to satisfy the Company's obligations under 3.1.4(R)(1)(a)
of the Disclosure and Transparency Rules ("DTRs"). In accordance with 3.1.5(R)
of the DTRs, the information required to be included in this notification was
received by the Company today, January 8, 2015.

For further information please contact:

Investor Relations                                                             
                                                                               
Jeff Poulton                            [email protected]   +1 781 482 0945   
                                                                               
Sarah Elton-Farr                        [email protected] +44 1256 894157   

NOTES TO EDITORS

Shire enables people with life-altering conditions to lead better lives.

Our strategy is to focus on developing and marketing innovative specialty
medicines to meet significant unmet patient needs.

We focus on providing treatments in Rare Diseases, Neuroscience,
Gastrointestinal, and Internal Medicine and we are developing treatments for
symptomatic conditions treated by specialist physicians in other targeted
therapeutic areas, such as Ophthalmics.

www.shire.com
                                                                            
Registered in Jersey, No. 99854, 22 Grenville Street, St Helier, Jersey JE4 8PX

Press Release                                     
                                                  
www.shire.com

a d v e r t i s e m e n t